Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1107

1.

Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.

Smith PJ, Souès S, Gottlieb T, Falk SJ, Watson JV, Osborne RJ, Bleehen NM.

Br J Cancer. 1994 Nov;70(5):914-21.

2.
3.

Cell cycle checkpoint evasion and protracted cell cycle arrest in X-irradiated small-cell lung carcinoma cells.

Smith PJ, Wiltshire M, Chin SF, Rabbitts P, Souès S.

Int J Radiat Biol. 1999 Sep;75(9):1137-47.

PMID:
10528922
6.

Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells.

Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z.

Cancer Res. 1992 Nov 15;52(22):6200-8.

7.

Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.

Satterwhite DJ, White RL, Matsunami N, Neufeld KL.

Cancer Res. 2000 Dec 15;60(24):6989-94.

8.

Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.

Jain N, Lam YM, Pym J, Campling BG.

Cancer. 1996 May 1;77(9):1797-808.

9.
11.

p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.

Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ Jr, Magrath I, Kohn KW, O'Connor PM.

Cancer Res. 1994 Nov 15;54(22):5824-30.

12.

Etoposide (VP-16) elicits apoptosis following prolonged G2-M cell arrest in p53-mutated human non-small cell lung cancer cells.

Chiu CC, Li CH, Ung MW, Fuh TS, Chen WL, Fang K.

Cancer Lett. 2005 Jun 8;223(2):249-58. Epub 2004 Dec 15.

PMID:
15896459
13.
14.

Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.

Inaba M, Mitsuhashi J, Kawada S, Nakano H.

Jpn J Cancer Res. 1994 Feb;85(2):187-93.

PMID:
8144400
15.

Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.

Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SP.

Cancer Res. 1993 Oct 15;53(20):4866-73.

16.
19.

Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.

Yamazaki K, Isobe H, Hanada T, Betsuyaku T, Hasegawa A, Hizawa N, Ogura S, Kawakami Y.

Cancer Chemother Pharmacol. 1997;39(3):192-8.

PMID:
8996519
20.

Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.

Takano H, Kohno K, Ono M, Uchida Y, Kuwano M.

Cancer Res. 1991 Aug 1;51(15):3951-7.

Supplemental Content

Support Center